Author

Jaroslaw Leszczyszyn

EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC FINDINGS IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFLIXIMAB (CT-P13) SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL
EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC FINDINGS IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFLIXIMAB (CT-P13) SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL

Jaroslaw Leszczyszyn  et al.

EXPOSURE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) IN PATIENTS WITH ACTIVE CROHN'S DISEASE AND ULCERATIVE COLITIS: ANALYSIS FROM A MULTICENTER, RANDOMIZED CONTROLLED PIVOTAL TRIAL
EXPOSURE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) IN PATIENTS WITH ACTIVE CROHN'S DISEASE AND ULCERATIVE COLITIS: ANALYSIS FROM A MULTICENTER, RANDOMIZED CONTROLLED PIVOTAL TRIAL

Jaroslaw Leszczyszyn  et al.

ORAL RITLECITINIB AND BREPOCITINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: CHRONIC THERAPY DATA FROM THE VIBRATO UMBRELLA STUDY
ORAL RITLECITINIB AND BREPOCITINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: CHRONIC THERAPY DATA FROM THE VIBRATO UMBRELLA STUDY

Jaroslaw Leszczyszyn  et al.

ORAL RITLECITINIB AND BREPOCITINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: DATA FROM THE VIBRATO UMBRELLA STUDY
ORAL RITLECITINIB AND BREPOCITINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: DATA FROM THE VIBRATO UMBRELLA STUDY

Jaroslaw Leszczyszyn  et al.

BASELINE SERUM BIOMARKERS PREDICT CLINICAL EFFICACY AND TISSUE MOLECULAR RESPONSE TO INDUCTION THERAPY WITH RITLECITINIB, AN ORAL JAK3/TEC INHIBITOR, IN ULCERATIVE COLITIS (UC) (PHASE 2B VIBRATO STUDY)
BASELINE SERUM BIOMARKERS PREDICT CLINICAL EFFICACY AND TISSUE MOLECULAR RESPONSE TO INDUCTION THERAPY WITH RITLECITINIB, AN ORAL JAK3/TEC INHIBITOR, IN ULCERATIVE COLITIS (UC) (PHASE 2B VIBRATO STUDY)

Jaroslaw Leszczyszyn  et al.

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1

Jaroslaw Leszczyszyn  et al.

Item 1 - 6 / 6
1